Oxidative stress contributes to pulmonary hypertension in the transgenic (mRen2)27 rat

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 294, Issue 6, 2008, Pages

  DeMarco, Vincent G ^a,c   Habibi, Javad ^a,b   Whaley Connell, Adam T ^a,b   Schneider, Rebecca I ^a,b   Heller, Randall L ^a   Bosanquet, James P ^a   Hayden, Melvin R ^a   Delcour, Kimberly ^a   Cooper, S A ^a,b   Andresen, Bradley T ^a   Sowers, James R ^a,b   Dellsperger, Kevin C ^a  

^a University of Missouri   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c Univ of Missouri   (United States)

Author keywords

Angiotensin II; NADPH oxidase; Renin

Indexed keywords

ANGIOTENSIN II; CATALASE; PROTEIN P22; RAC1 PROTEIN; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 2; RENIN; SUPEROXIDE DISMUTASE; TEMPOL; AMINE OXIDE; ANTIOXIDANT; CYBB PROTEIN, RAT; MEMBRANE PROTEIN; P22 PHOX PROTEIN, RAT; P22-PHOX PROTEIN, RAT; RAC1 PROTEIN, RAT; REN2 PROTEIN, MOUSE;

ADOLESCENT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; HEART LEFT VENTRICLE HYPERTROPHY; HEART RIGHT VENTRICLE HYPERTROPHY; HEART VENTRICLE PRESSURE; HORMONE SYNTHESIS; HYPERTENSION; MALE; MEAN ARTERIAL PRESSURE; NONHUMAN; NUCLEOTIDE SEQUENCE; OXIDATIVE STRESS; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RAT; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SYSTOLIC BLOOD PRESSURE; TRANSGENIC RAT; ANIMAL; BLOOD PRESSURE; DISEASE MODEL; DRUG EFFECT; ENZYMOLOGY; GENETICS; HEART RIGHT VENTRICLE FUNCTION; LUNG; METABOLISM; MOUSE; PATHOLOGY; PATHOPHYSIOLOGY; PULMONARY ARTERY; SPIN LABELING; SPRAGUE DAWLEY RAT; TRANSGENIC ANIMAL;

ANIMALS; ANIMALS, GENETICALLY MODIFIED; ANTIOXIDANTS; BLOOD PRESSURE; CYCLIC N-OXIDES; DISEASE MODELS, ANIMAL; HYPERTENSION, PULMONARY; HYPERTROPHY, LEFT VENTRICULAR; HYPERTROPHY, RIGHT VENTRICULAR; LUNG; MALE; MEMBRANE GLYCOPROTEINS; MICE; NADPH OXIDASE; OXIDATIVE STRESS; PULMONARY ARTERY; RAC1 GTP-BINDING PROTEIN; RATS; RATS, SPRAGUE-DAWLEY; REACTIVE OXYGEN SPECIES; RENIN; RENIN-ANGIOTENSIN SYSTEM; SPIN LABELS; VENTRICULAR FUNCTION, RIGHT; VENTRICULAR PRESSURE;

EID: 49249118303     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.00953.2007     Document Type: Article

References (79)

1. rac1. Nature 353: 668-670, 1991.
2. Aldashev AA, Sarybaev AS, Sydykov AS, Kalmyrzaev BB, Kim EV, Mamanova LB, Maripov R, Kojonazarov BK, Mirrakhimov MM, Wilkins MR, Morrell NW. Characterization of high-altitude pulmonary hypertension in the Kyrgyz: association with angiotensin-converting enzyme genotype. Am J Respir Crit Care Med 166: 1396-1402, 2002.
3. Alpert MA, Pressly TA, Mukerji V, Lambert CR, Mukerji B. Short-and long-term hemodynamic effects of captopril in patients with pulmonary hypertension and selected connective tissue disease. Chest 102: 1407-1412, 1992.
4. Bachmann S, Peters J, Engler E, Ganten D, Mullins J. Transgenic rats carrying the mouse renin gene - morphological characterization of a low-renin hypertension model. Kidney Int 41: 24-36, 1992.
5. Blendea MC, Jacobs D, Stump CS, McFarlane SI, Ogrin C, Bahtyiar G, Stas S, Kumar P, Sha Q, Ferrario CM, Sowers JR. Abrogation of oxidative stress improves insulin sensitivity in the Ren-2 rat model of tissue angiotensin II overexpression. Am J Physiol Endocrinol Metab 288: E353-E359, 2005.
6. Butorov IV, Verbitskii ON, Butorov SI. Blockers of angiotensin receptors: a novel approach to the treatment of secondary pulmonary hypertension [in Russian]. Ter Arkh 76: 84-87, 2004.
7. Cai H, Griendling KK, Harrison DG. The vascular NAD(P)H oxidases as therapeutic targets in cardiovascular diseases. Trends Pharmacol Sci 24: 471-478, 2003.
8. Campbell DJ, Rong P, Kladis A, Rees B, Ganten D, Skinner SL. Angiotensin and bradykinin peptides in the TGR(mRen-2)27 rat. Hypertension 25: 1014-1020, 1995.
9. Cassis LA, Rippetoe PE, Soltis EE, Painter DJ, Fitz R, Gillespie MN. Angiotensin II and monocrotaline-induced pulmonary hypertension: effect of losartan (DuP 753), a nonpeptide angiotensin type 1 receptor antagonist. J Pharmacol Exp Ther 262: 1168-1172, 1992.
10. Chalupsky K, Cai H. Endothelial dihydrofolate reductase: critical for nitric oxide bioavailability and role in angiotensin II uncoupling of endothelial nitric oxide synthase. Proc Natl Acad Sci USA 102: 9056-9061, 2005.
11. Chassagne C, Eddahibi S, Adamy C, Rideau D, Marotte F, Dubois-Rande JL, Adnot S, Samuel JL, Teiger E. Modulation of angiotensin II receptor expression during development and regression of hypoxic pulmonary hypertension. Am J Respir Cell Mol Biol 22: 323-332, 2000.
12. Chen Y, Pearlman A, Luo Z, Wilcox CS. Hydrogen peroxide mediates a transient vasorelaxation with tempol during oxidative stress. Am J Physiol Heart Circ Physiol 293: H2085-H2092, 2007.
13. Clempus RE, Griendling KK. Reactive oxygen species signaling in vascular smooth muscle cells. Cardiovasc Res 71: 216-225, 2006.
14. Griendling KK. Novel NAD(P)H oxidases in the cardiovascular system. Heart 90: 491-493, 2004.
15. Griendling KK, Minieri CA, Ollerenshaw JD, Alexander RW. Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circ Res 74: 1141-1148, 1994.
16. Griendling KK, Sorescu D, Lassegue B, Ushio-Fukai M. Modulation of protein kinase activity and gene expression by reactive oxygen species and their role in vascular physiology and pathophysiology. Arterioscler Thromb Vasc Biol 20: 2175-2183, 2000.
17. Griendling KK, Sorescu D, Ushio-Fukai M. NAD(P)H oxidase: role in cardiovascular biology and disease. Circ Res 86: 494-501, 2000.
18. Griendling KK, Ushio-Fukai M. Reactive oxygen species as mediators of angiotensin II signaling. Regul Pept 91: 21-27, 2000.
19. Grobe AC, Wells SM, Benavidez E, Oishi P, Azakie A, Fineman JR, Black SM. Increased oxidative stress in lambs with increased pulmonary blood flow and pulmonary hypertension: role of NADPH oxidase and endothelial NO synthase. Am J Physiol Lung Cell Mol Physiol 290: L1069-L1077, 2006.
20. Guo P, Nishiyama A, Rahman M, Nagai Y, Noma T, Namba T, Ishizawa M, Murakami K, Miyatake A, Kimura S, Mizushige K, Abe Y, Ohmori K, Kohno M. Contribution of reactive oxygen species to the pathogenesis of left ventricular failure in Dahl salt-sensitive hypertensive rats: effects of angiotensin II blockade. J Hypertens 24: 1097-1104, 2006.
21. Habibi J, Whaley-Connell A, Qazi MA, Hayden MR, Cooper SA, Tramontano A, Thyfault J, Stump C, Ferrario C, Muniyappa R, Sowers JR. Rosuvastatin, a HMG-CoA reductase inhibitor, decreases cardiac oxidative stress and remodeling in Ren2 transgenic rats. Endocrinology 148: 1281-1288, 2007.
22. Harrison D, Griendling KK, Landmesser U, Hornig B, Drexler H. Role of oxidative stress in atherosclerosis. Am J Cardiol 91: 7A-11A, 2003.
23. Hilgers KF, Peters J, Veelken R, Sommer M, Rupprecht G, Ganten D, Luft FC, Mann JF. Increased vascular angiotensin formation in female rats harboring the mouse Ren-2 gene. Hypertension 19: 687-691, 1992.
24. Jasmin JF, Calderone A, Leung TK, Villeneuve L, Dupuis J. Lung structural remodeling and pulmonary hypertension after myocardial infarction: complete reversal with irbesartan. Cardiovasc Res 58: 621-631, 2003.
25. Jasmin JF, Cernacek P, Dupuis J. Activation of the right ventricular endothelin (ET) system in the monocrotaline model of pulmonary hypertension: response to chronic ETA receptor blockade. Clin Sci (Lond) 105: 647-653, 2003.
26. Javesghani D, Magder SA, Barreiro E, Quinn MT, Hussain SN. Molecular characterization of a superoxide-generating NAD(P)H oxidase in the ventilatory muscles. Am J Respir Crit Care Med 165: 412-418, 2002.
27. Kakinuma Y, Miyauchi T, Suzuki T, Yuki K, Murakoshi N, Goto K, Yamaguchi I. Enhancement of glycolysis in cardiomyocytes elevates endothelin-1 expression through the transcriptional factor hypoxia-inducible factor-1α. Clin Sci (Lond) 103 Suppl 48: 210S-214S, 2002.
28. Kanazawa H, Otsuka T, Hirata K, Yoshikawa J. Association between the angiotensin-converting enzyme gene polymorphisms and tissue oxygenation during exercise in patients with COPD. Chest 121: 697-701, 2002.
29. Kanno S, Wu YJ, Lee PC, Billiar TR, Ho C. Angiotensin-converting enzyme inhibitor preserves p21 and endothelial nitric oxide synthase expression in monocrotaline-induced pulmonary arterial hypertension in rats. Circulation 104: 945-950, 2001.
30. Kiely DG, Cargill RI, Wheeldon NM, Coutie WJ, Lipworth BJ. Haemodynamic and endocrine effects of type 1 angiotensin II receptor blockade in patients with hypoxaemic cor pulmonale. Cardiovasc Res 33: 201-208, 1997.
31. Kreutz R, Fernandez-Alfonso MS, Ganten D, Paul M. Effect of losartan on right ventricular hypertrophy and cardiac angiotensin I-converting enzyme activity in pulmonary hypertensive rats. Clin Exp Hypertens 18: 101-111, 1996.
32. Landmesser U, Spiekermann S, Preuss C, Sorrentino S, Fischer D, Manes C, Mueller M, Drexler H. Angiotensin II induces endothelial xanthine oxidase activation: role for endothelial dysfunction in patients with coronary disease. Arterioscler Thromb Vasc Biol 27: 943-948, 2007.
33. Lee MA, Bohm M, Paul M, Bader M, Ganten U, Ganten D. Physiological characterization of the hypertensive transgenic rat TGR(mREN2)27. Am J Physiol Endocrinol Metab 270: E919-E929, 1996.
34. Lefebvre F, Prefontaine A, Calderone A, Caron A, Jasmin JF, Villeneuve L, Dupuis J. Modification of the pulmonary renin-angiotensin system and lung structural remodelling in congestive heart failure. Clin Sci (Lond) 111: 217-224, 2006.
35. Leier CV, Bambach D, Nelson S, Hermiller JB, Huss P, Magorien RD, Unverferth DV. Captopril in primary pulmonary hypertension. Circulation 67: 155-161, 1983.
36. Liu JQ, Zelko IN, Erbynn EM, Sham JS, Folz RJ. Hypoxic pulmonary hypertension: role of superoxide and NADPH oxidase (gp91phox). Am J Physiol Lung Cell Mol Physiol 290: L2-L10, 2006.
37. Mittal M, Roth M, Konig P, Hofmann S, Dony E, Goyal P, Selbitz AC, Schermuly RT, Ghofrani HA, Kwapiszewska G, Kummer W, Klepetko W, Hoda MA, Fink L, Hanze J, Seeger W, Grimminger F, Schmidt HH, Weissmann N. Hypoxia-dependent regulation of non-phagocytic NADPH oxidase subunit NOX4 in the pulmonary vasculature. Circ Res 101: 258-267, 2007.
38. Molteni A, Ward WF, Ts'ao CH, Solliday NH. Monocrotaline-induced cardiopulmonary damage in rats: amelioration by the angiotensin-converting enzyme inhibitor CL242817. Proc Soc Exp Biol Med 182: 483-493, 1986.
39. Molteni A, Ward WF, Ts'ao CH, Solliday NH, Dunne M. Monocrotaline-induced pulmonary fibrosis in rats: amelioration by captopril and penicillamine. Proc Soc Exp Biol Med 180: 112-120, 1985.
40. Moriguchi A, Brosnihan KB, Kumagai H, Ganten D, Ferrario CM. Mechanisms of hypertension in transgenic rats expressing the mouse Ren-2 gene. Am J Physiol Regul Integr Comp Physiol 266: R1273-R1279, 1994.
41. Morrell NW, Atochina EN, Morris KG, Danilov SM, Stenmark KR. Angiotensin converting enzyme expression is increased in small pulmonary arteries of rats with hypoxia-induced pulmonary hypertension. J Clin Invest 96: 1823-1833, 1995.
42. Morrell NW, Danilov SM, Satyan KB, Morris KG, Stenmark KR. Right ventricular angiotensin converting enzyme activity and expression is increased during hypoxic pulmonary hypertension. Cardiovasc Res 34: 393-403, 1997.
43. Morrell NW, Morris KG, Stenmark KR. Role of angiotensin-converting enzyme and angiotensin II in development of hypoxic pulmonary hypertension. Am J Physiol Heart Circ Physiol 269: H1186-H1194, 1995.
44. Morris BJ, Pinet F, Michel JB, Soubrier F, Corvol P. Renin secretion from malignant pulmonary metastatic tumour cells of vascular origin. Clin Exp Pharmacol Physiol 14: 227-231, 1987.
45. Mullins JJ, Peters J, Ganten D. Fulminant hypertension in transgenic rats harbouring the mouse Ren-2 gene. Nature 344: 541-544, 1990.
46. Myhre O, Andersen JM, Aarnes H, Fonnum F. Evaluation of the probes 2′,7′-dichlorofluorescin diacetate, luminol, and lucigenin as indicators of reactive species formation. Biochem Pharmacol 65: 1575-1582, 2003.
47. Nguyen G, Delarue F, Burckle C, Bouzhir L, Giller T, Sraer JD. Pivotal role of the renin/prorenin receptor in angiotensin II production and cellular responses to renin. J Clin Invest 109: 1417-1427, 2002.
48. Nong Z, Stassen JM, Moons L, Collen D, Janssens S. Inhibition of tissue angiotensin-converting enzyme with quinapril reduces hypoxic pulmonary hypertension and pulmonary vascular remodeling. Circulation 94: 1941-1947, 1996.
49. Okada K, Bernstein ML, Zhang W, Schuster DP, Botney MD. Angiotensin-converting enzyme inhibition delays pulmonary vascular neointimal formation. Am J Respir Crit Care Med 158: 939-950, 1998.
50. Opocensky M, Dvorak P, Maly J, Kramer HJ, Backer A, Kopkan L, Vernerova Z, Tesar V, Zima T, Bader M, Ganten D, Janda J, Vaneckova I. Chronic endothelin receptor blockade reduces end-organ damage independently of blood pressure effects in salt-loaded heterozygous Ren-2 transgenic rats. Physiol Res 53: 581-593, 2004.
51. Orte C, Polak JM, Haworth SG, Yacoub MH, Morrell NW. Expression of pulmonary vascular angiotensin-converting enzyme in primary and secondary plexiform pulmonary hypertension. J Pathol 192: 379-384, 2000.
52. Parinandi NL, Kleinberg MA, Usatyuk PV, Cummings RJ, Pennathur A, Cardounel AJ, Zweier JL, Garcia JG, Natarajan V. Hyperoxia-induced NAD(P)H oxidase activation and regulation by MAP kinases in human lung endothelial cells. Am J Physiol Lung Cell Mol Physiol 284: L26-L38, 2003.
53. Pinto YM, Buikema H, van Gilst WH, Scholtens E, van Geel PP, de Graeff PA, Wagner J, Paul M. Cardiovascular end-organ damage in Ren-2 transgenic rats compared to spontaneously hypertensive rats. J Mol Med 75: 371-377, 1997.
54. Ritchie RH, Quinn JM, Cao AH, Drummond GR, Kaye DM, Favaloro JM, Proietto J, Delbridge LM. The antioxidant tempol inhibits cardiac hypertrophy in the insulin-resistant GLUT4-deficient mouse in vivo. J Mol Cell Cardiol 42: 1119-1128, 2007.
55. Rondelet B, Kerbaul F, van Beneden R, Hubloue I, Huez S, Fesler P, Remmelink M, Brimioulle S, Salmon I, Naeije R. Prevention of pulmonary vascular remodelling and of decreased BMPR-2 expression by losartan therapy in shunt-induced pulmonary hypertension. Am J Physiol Heart Circ Physiol 289: H2319-H2324, 2005.
56. Rossi GP, Sacchetto A, Rizzoni D, Bova S, Porteri E, Mazzocchi G, Belloni AS, Bahcelioglu M, Nussdorfer GG, Pessina AC. Blockade of angiotensin II type 1 receptor and not of endothelin receptor prevents hypertension and cardiovascular disease in transgenic (mREN2)27 rats via adrenocortical steroid-independent mechanisms. Arterioscler Thromb Vasc Biol 20: 949-956, 2000.
57. Rothermund L, Pinto YM, Hocher B, Vetter R, Leggewie S, Kobetamehl P, Orzechowski HD, Kreutz R, Paul M. Cardiac endothelin system impairs left ventricular function in renin-dependent hypertension via decreased sarcoplasmic reticulum Ca2- uptake. Circulation 102: 1582-1588, 2000.
58. 558: the flavin-binding component of the phagocyte NADPH oxidase. Science 256: 1459-1462, 1992.
59. 2α. Hypertension 33: 424-428, 1999.
60. Sealey JE, Catanzaro DF, Lavin TN, Gahnem F, Pitarresi T, Hu LF, Laragh JH. Specific prorenin/renin binding (ProBP). Identification and characterization of a novel membrane site. Am J Hypertens 9: 491-502, 1996.
61. Seccia TM, Belloni AS, Kreutz R, Paul M, Nussdorfer GG, Pessina AC, Rossi GP. Cardiac fibrosis occurs early and involves endothelin and AT-1 receptors in hypertension due to endogenous angiotensin II. J Am Coll Cardiol 41: 666-673, 2003.
62. Seshiah PN, Weber DS, Rocic P, Valppu L, Taniyama Y, Griendling KK. Angiotensin II stimulation of NAD(P)H oxidase activity: upstream mediators. Circ Res 91: 406-413, 2002.
63. Sigmund CD, Gross KW. Structure, expression, and regulation of the murine renin genes. Hypertension 18: 446-457, 1991.
64. Stumpe KO, Schmengler K, Bette L, Overlack A, Kolloch R. Persistent hemodynamic and clinical improvement after captopril in patients with pulmonary hypertension. Herz 11: 217-225, 1986.
65. Sturrock A, Cahill B, Norman K, Huecksteadt TP, Hill K, Sanders K, Karwande SV, Stringham JC, Bull DA, Gleich M, Kennedy TP, Hoidal JR. Transforming growth factor-β1 induces Nox4 NAD(P)H oxidase and reactive oxygen species-dependent proliferation in human pulmonary artery smooth muscle cells. Am J Physiol Lung Cell Mol Physiol 290: L661-L673, 2006.
66. Tanabe N, Amano S, Tatsumi K, Kominami S, Igarashi N, Shimura R, Matsubara H, Kasahara Y, Takiguchi Y, Kuriyama T. Angiotensin-converting enzyme gene polymorphisms and prognosis in chronic thromboembolic pulmonary hypertension. Circ J 70: 1174-1179, 2006.
67. Taylor GM, Cook HT, Hanson C, Peart WS, Zondek T, Zondek LH. Renin in human fetal lung - a biochemical and immunohistochemical study. J Hypertens 6: 845-851, 1988.
68. Taylor GM, Cook HT, Sheffield EA, Hanson C, Peart WS. Renin in blood vessels in human pulmonary tumors. An immunohistochemical and biochemical study. Am J Pathol 130: 543-551, 1988.
69. Ushio-Fukai M, Griendling KK, Becker PL, Hilenski L, Halleran S, Alexander RW. Epidermal growth factor receptor transactivation by angiotensin II requires reactive oxygen species in vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 21: 489-495, 2001.
70. Valencia JC, Pacheco-Rodriguez G, Carmona AK, Xavier J, Bruneval P, Riemenschneider WK, Ikeda Y, Yu ZX, Ferrans VJ, Moss J. Tissue-specific renin-angiotensin system in pulmonary lymphangio-leiomyomatosis. Am J Respir Cell Mol Biol 35: 40-47, 2006.
71. Van Suylen RJ, Aartsen WM, Smits JF, Daemen MJ. Dissociation of pulmonary vascular remodeling and right ventricular pressure in tissue angiotensin-converting enzyme-deficient mice under conditions of chronic alveolar hypoxia. Am J Respir Crit Care Med 163: 1241-1245, 2001.
72. Van Suylen RJ, Smits JF, Daemen MJ. Pulmonary artery remodeling differs in hypoxia- and monocrotaline-induced pulmonary hypertension. Am J Respir Crit Care Med 157: 1423-1428, 1998.
73. Wei Y, Whaley-Connell AT, Chen K, Habibi J, Uptergrove GM, Clark SE, Stump CS, Ferrario CM, Sowers JR. NADPH oxidase contributes to vascular inflammation, insulin resistance, and remodeling in the transgenic (mRen2) rat. Hypertension 50: 384-391, 2007.
74. Welch WJ, Mendonca M, Blau J, Karber A, Dennehy K, Patel K, Lao YS, Jose PA, Wilcox CS. Antihypertensive response to prolonged tempol in the spontaneously hypertensive rat. Kidney Int 68: 179-187, 2005.
75. Whaley-Connell A, Chowdhury N, Hayden MR, Stump CS, Habibi J, Wiedmeyer CE, Gallagher PE, Tallant EA, Cooper SA, Link CD, Ferrario CM, Sowers JR. Oxidative stress and glomerular filtration barrier injury: role of the renin-angiotensin system in the Ren2 transgenic rat. Am J Physiol Renal Physiol 291: F1308-F1314, 2006.
76. Whaley-Connell A, Govindarajan G, Habibi J, Hayden MR, Cooper SA, Wei Y, Ma L, Qazi M, Link D, Karuparthi PR, Stump CS, Ferrario CM, Sowers JR. Angiotensin-II mediated oxidative stress promotes myocardial tissue remodeling in the transgenic (mRen2)27 Ren2 rat. Am J Physiol Endocrinol Metab 293: E355-E363, 2007.
77. Xu H, Fink GD, Galligan JJ. Nitric oxide-independent effects of tempol on sympathetic nerve activity and blood pressure in DOCA-salt rats. Am J Physiol Heart Circ Physiol 283: H885-H892, 2002.
78. Xu H, Jackson WF, Fink GD, Galligan JJ. Activation of potassium channels by tempol in arterial smooth muscle cells from normotensive and deoxycorticosterone acetate-salt hypertensive rats. Hypertension 48: 1080-1087, 2006.
79. Zhao Y, Bader M, Kreutz R, Fernandez-Alfonso M, Zimmermann F, Ganten U, Metzger R, Ganten D, Mullins JJ, Peters J. Ontogenetic regulation of mouse Ren-2d renin gene in transgenic hypertensive rats, TGR(mREN2)27. Am J Physiol Endocrinol Metab 265: E699-E707, 1993.